Stock Financial Ratios

ACOR / Acorda Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price25.80
Volume645,700.00
Market Cap ($M)1,086.55
Enterprise Value ($M)929.24
Book Value ($M)664.21
Book Value / Share14.31
Price / Book1.73
NCAV ($M)229.44
NCAV / Share19.28
Price / NCAV4.58
Income Statement (mra) ($M)
Revenue519.60
EBITDA-35.98
Net Income-35.60
Balance Sheet (mrq) ($M)
Cash & Equivalents192.50
Cash / Share4.25
Assets0.00
Liabilities665.07
Quick Ratio1.62
Current Ratio1.62
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.05
Return on Assets (ROA)-0.04
Return on Equity (ROE)-0.05
Identifiers and Descriptors
CUSIP00484M106
Central Index Key (CIK)1008848
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
00484M956
00484M906
Share Statistics
Weighted Average Number Of Shares Outstanding Basic45,259,000
Common Shares Outstanding46,407,850
Weighted Average Number Of Diluted Shares Outstanding45,259,000
Common Stock Shares Outstanding45,680,042
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Equity Per Share0.00
Liabilities Current Per Share0.00
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Cash Per Share4.25
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Accounts Receivable Per Share1.16
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Treasury Stock Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Cash And Equivalents Per Share4.15
Liabilities Per Share14.69
Assets Current Per Share6.54
Assets Other Non Current Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00

Related News Stories

Acorda Therapeutics, Inc. 2017 Q4 - Results - Earnings Call Slides

2018-02-16 seekingalpha
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2017 Q4 earnings call. (12-0)

Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

2018-02-16 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) reported adjusted earnings of 61 cents per share in the fourth quarter of 2017, which missed the Zacks Consensus Estimate of $1.09. However, the bottom line significantly increased from the year-ago figure of 5 cents. (97-0)

Top Analyst Upgrades and Downgrades: Alarm.com, Biogen, Blue Apron, Cisco, Lowe’s, Pandora, Waste Management and More

2018-02-16 247wallst
This week has been a wild ride, and stocks were looking for direction based on more inflationary concerns after the import prices were hotter than expected. The bull market is now just three weeks shy of being nine years old. No trend can last forever, but the one that keeps proving to be right is that investors have been rewarded handily buying the pullbacks. Now investors still have to decide how they want to be positioned for 2018 and beyond. (177-1)

Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call Transcript

2018-02-15 seekingalpha
Welcome to the Acorda Therapeutics' Fourth Quarter 2017 Updates. At this time, all participants are in a listen-only mode. There will be a question-and-answer-session to follow. Please be advised that this call being taped at the company's request. (12-0)

Spirit Airlines (SAVE) Beats on Q4 Earnings

2018-02-06 zacks
Spirit Airlines (SAVE - Free Report) reported fourth-quarter 2017 earnings per share (on an adjusted basis) of 73 cents, beating the Zacks Consensus Estimate of 71 cents. Earnings, however, decreased  on a year-over-year basis due to higher costs. (15-0)

CUSIP: 00484M106